{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:14Z","timestamp":1793039894604,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["T2225021"],"award-info":[{"award-number":["T2225021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20378"],"award-info":[{"award-number":["U20A20378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-01078-y","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:02:15Z","timestamp":1768557735000},"page":"207-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy"],"prefix":"10.1038","volume":"7","author":[{"given":"Xiaohong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-1834","authenticated-orcid":false,"given":"Yuxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9189-602X","authenticated-orcid":false,"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunqiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-3187","authenticated-orcid":false,"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-7721","authenticated-orcid":false,"given":"Yuan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-3353","authenticated-orcid":false,"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"1078_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc6659","volume":"12","author":"S Atasheva","year":"2020","unstructured":"Atasheva, S. et al. Systemic cancer therapy with engineered adenovirus that evades innate immunity. Sci. Transl. Med. 12, eabc6659 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1078_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin, L. et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci. Transl. Med. 14, eabn2231 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1078_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","volume":"12","author":"AK Park","year":"2020","unstructured":"Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","volume":"286","author":"AF Ochsenbein","year":"1999","unstructured":"Ochsenbein, A. F. et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286, 2156\u20132159 (1999).","journal-title":"Science"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"108351","DOI":"10.1016\/j.clim.2020.108351","volume":"212","author":"BE Maloney","year":"2020","unstructured":"Maloney, B. E., Perera, K. D., Saunders, D. R. D., Shadipeni, N. & Fleming, S. D. Interactions of viruses and the humoral innate immune response. Clin. Immunol. 212, 108351 (2020).","journal-title":"Clin. Immunol."},{"key":"1078_CR6","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/0008-5472.CAN-13-3306","volume":"74","author":"A Muik","year":"2014","unstructured":"Muik, A. et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res. 74, 3567\u20133578 (2014).","journal-title":"Cancer Res."},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559\u2013567 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher, A., Harrington, K. & Vile, R. Oncolytic virotherapy as immunotherapy. Science 374, 1325\u20131326 (2021).","journal-title":"Science"},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian, Y., Xie, D. & Yang, L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Sig. Transduct. Target. Ther. 7, 117 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"1078_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99\u2013102 (2011).","journal-title":"Nature"},{"key":"1078_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Sig. Transduct. Target. Ther. 8, 156 (2023).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","volume":"148","author":"S La Salvia","year":"2023","unstructured":"La Salvia, S. et al. Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart. Circulation 148, 405\u2013425 (2023).","journal-title":"Circulation"},{"key":"1078_CR13","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","volume":"5","author":"JD Rubinstein","year":"2021","unstructured":"Rubinstein, J. D. et al. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. Blood Adv. 5, 3309\u20133321 (2021).","journal-title":"Blood Adv."},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","volume":"40","author":"N Zheng","year":"2022","unstructured":"Zheng, N. et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell 40, 973\u2013985.e7 (2022).","journal-title":"Cancer Cell"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","volume":"19","author":"P Lv","year":"2019","unstructured":"Lv, P. et al. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy. Nano Lett. 19, 2993\u20133001 (2019).","journal-title":"Nano Lett."},{"key":"1078_CR16","doi-asserted-by":"crossref","unstructured":"Chen, Y. et al. An oncolytic virus\u2013T cell chimera for cancer immunotherapy Nat. Biotechnol. 42, 1876\u20131887 (2024).","DOI":"10.1038\/s41587-023-02118-7"},{"key":"1078_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010239","volume":"7","author":"S Mattapally","year":"2018","unstructured":"Mattapally, S. et al. Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy. J. Am. Heart Assoc. 7, e010239 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609, 369\u2013374 (2022).","journal-title":"Nature"},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cellimm.2018.06.003","volume":"331","author":"S Bansal","year":"2018","unstructured":"Bansal, S., Sharma, M., Ranjithkumar, R. & Mohanakumar, T. The role of exosomes in allograft immunity. Cell. Immunol. 331, 85\u201392 (2018).","journal-title":"Cell. Immunol."},{"key":"1078_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7577","volume":"10","author":"A Samson","year":"2018","unstructured":"Samson, A. et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci. Transl. Med. 10, eaam7577 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","volume":"13","author":"V Sivanandam","year":"2019","unstructured":"Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y. & Warner, S. G. Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol. Ther. Oncolytics 13, 93\u2013106 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1078_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio, F. G. et al. Tumor burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 19, 75\u201390 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz, P., Pelegrin, P. & Shao, F. The gasdermins, a protein family executing cell death and inflammation. Nat. Rev. Immunol. 20, 143\u2013157 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41573-021-00154-z","volume":"20","author":"X Liu","year":"2021","unstructured":"Liu, X., Xia, S., Zhang, Z., Wu, H. & Lieberman, J. Channelling inflammation: gasdermins in physiology and disease. Nat. Rev. Drug Discov. 20, 384\u2013405 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1078_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35917-2","volume":"14","author":"J Lin","year":"2023","unstructured":"Lin, J. et al. Oncolytic Parapoxvirus induces gasdermin E-mediated pyroptosis and activates antitumor immunity. Nat. Commun. 14, 224 (2023).","journal-title":"Nat. Commun."},{"key":"1078_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111148","volume":"27","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer. iScience 27, 111148 (2024).","journal-title":"iScience"},{"key":"1078_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27407-0","volume":"12","author":"Y Lu","year":"2021","unstructured":"Lu, Y. et al. Strategies to package recombinant adeno-associated virus expressing the N-terminal gasdermin domain for tumor treatment. Nat. Commun. 12, 7155 (2021).","journal-title":"Nat. Commun."},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41565-022-01125-0","volume":"17","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. A pyroptosis nanotuner for cancer therapy. Nat. Nanotechnol. 17, 788\u2013798 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660\u2013665 (2015).","journal-title":"Nature"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41565-023-01378-3","volume":"18","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Non-invasive manipulation of intratumoral genome editing activates adoptive T-cell therapy against solid tumors. Nat. Nanotechnol. 18, 933\u2013944 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"1078_CR31","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1073\/pnas.1912220117","volume":"117","author":"X Chen","year":"2020","unstructured":"Chen, X., Chen, Y., Xin, H., Wan, T. & Ping, Y. Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing. Proc. Natl Acad. Sci. USA 117, 2395\u20132405 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1078_CR32","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. Control of the activity of CAR-T cells within tumors via focused ultrasound. Nat. Biomed. Eng. 5, 1336\u20131347 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","volume":"5","author":"IC Miller","year":"2021","unstructured":"Miller, I. C. et al. Enhanced intratumoral activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat. Biomed. Eng. 5, 1348\u20131359 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1038\/s41596-019-0240-9","volume":"14","author":"K Matsumoto","year":"2019","unstructured":"Matsumoto, K. et al. Advanced CUBIC tissue clearing for whole-organ cell profiling. Nat. Protoc. 14, 3506\u20133537 (2019).","journal-title":"Nat. Protoc."},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119 (2017).","journal-title":"Cell"},{"key":"1078_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang, T., Ren, Y., Yang, P., Wang, J. & Zhou, H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 13, 897 (2022).","journal-title":"Cell Death Dis."},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41563-024-01908-x","volume":"23","author":"BL LeSavage","year":"2024","unstructured":"LeSavage, B. L. et al. Engineered matrices reveal stiffness-mediated chemoresistance in patient-derived pancreatic cancer organoids. Nat. Mater. 23, 1138\u20131149 (2024).","journal-title":"Nat. Mater."},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"1078_CR39","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2014.41","volume":"28","author":"L Kordelas","year":"2014","unstructured":"Kordelas, L. et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28, 970\u2013973 (2014).","journal-title":"Leukemia"},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41551-023-01142-x","volume":"8","author":"DM Stranford","year":"2024","unstructured":"Stranford, D. M. et al. Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells. Nat. Biomed. Eng. 8, 397\u2013414 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1078_CR41","doi-asserted-by":"publisher","first-page":"2001108","DOI":"10.1002\/advs.202001108","volume":"7","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Choice of nanovaccine delivery mode has profound impacts on the intralymph node spatiotemporal distribution and immunotherapy efficacy. Adv. Sci. 7, 2001108 (2020).","journal-title":"Adv. Sci."},{"key":"1078_CR42","doi-asserted-by":"publisher","first-page":"24641","DOI":"10.3402\/jev.v3.24641","volume":"3","author":"LA Mulcahy","year":"2014","unstructured":"Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles. 3, 24641 (2014).","journal-title":"J. Extracell. Vesicles."},{"key":"1078_CR43","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","volume":"5","author":"KD Popowski","year":"2022","unstructured":"Popowski, K. D. et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter 5, 2960\u20132974 (2022).","journal-title":"Matter"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41551-022-00902-5","volume":"6","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791\u2013805 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1078_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1685","volume":"6","author":"S Hu","year":"2020","unstructured":"Hu, S. et al. Dermal exosomes containing miR-218-5p promote hair regeneration by regulating \u03b2-catenin signaling. Sci. Adv. 6, eaba1685 (2020).","journal-title":"Sci. Adv."},{"key":"1078_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41565-023-01533-w","volume":"19","author":"N Krishnan","year":"2024","unstructured":"Krishnan, N. et al. A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering. Nat. Nanotechnol. 19, 345\u2013353 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"1078_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28108","volume":"95","author":"Y Shen","year":"2023","unstructured":"Shen, Y. et al. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. J. Med. Virol. 95, e28108 (2023).","journal-title":"J. Med. Virol."},{"key":"1078_CR48","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41563-023-01630-0","volume":"22","author":"LNM Nguyen","year":"2023","unstructured":"Nguyen, L. N. M. et al. The exit of nanoparticles from solid tumors. Nat. Mater. 22, 1261\u20131272 (2023).","journal-title":"Nat. Mater."},{"key":"1078_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb9484","volume":"6","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. A versatile genetic control system in mammalian cells and mice responsive to clinically licensed sodium ferulate. Sci. Adv. 6, eabb9484 (2020).","journal-title":"Sci. Adv."},{"key":"1078_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41589-021-00899-z","volume":"18","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Genetic-code-expanded cell-based therapy for treating diabetes in mice. Nat. Chem. Biol. 18, 47\u201355 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1078_CR51","doi-asserted-by":"publisher","unstructured":"Li, B. et al. Supramolecular genome editing: targeted delivery and endogenous activation of CRISPR\/Cas9 by dynamic host-guest recognition. Angew. Chem. Int. Ed. https:\/\/doi.org\/10.1002\/ange.202316323 (2024).","DOI":"10.1002\/ange.202316323"},{"key":"1078_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/cgt.2010.62","volume":"18","author":"SL Longo","year":"2011","unstructured":"Longo, S. L., Griffith, C., Glass, A., Shillitoe, E. J. & Post, D. E. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter. Cancer Gene Ther. 18, 123\u2013134 (2011).","journal-title":"Cancer Gene Ther."},{"key":"1078_CR53","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1042\/BJ20150204","volume":"468","author":"P Shi","year":"2015","unstructured":"Shi, P. et al. Loss of conserved Gsdma3 self-regulation causes autophagy and cell death. Biochem. J. 468, 325\u2013326 (2015).","journal-title":"Biochem. J"},{"key":"1078_CR54","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1126\/science.aay9207","volume":"368","author":"S Balint","year":"2020","unstructured":"Balint, S. et al. Supramolecular attack particles are autonomous killing entities released from cytotoxic T cells. Science 368, 897\u2013901 (2020).","journal-title":"Science"},{"key":"1078_CR55","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707\u2013716 (2018).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01078-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01078-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:02:41Z","timestamp":1769846561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01078-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01078-y","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.C., Y.C. and Y.P. are listed as inventors on a patent application (CN2025116032782, \u2018An Engineered Membrane-Armed Oncolytic Virus Formulation for Systemic Administration and Preparation Method Thereof\u2019), submitted by Zhejiang University and related to this work. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}